Medmonitor

A biosimilar to Stelara, this drug is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderate to severe Crohn’s disease, and moderate to severe ulcerative colitis

Indicated for the treatment of opioid-induced constipation

An opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids.

Indicated for the mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults

Indicated for the emergency treatment of type I allergic reactions, including anaphylaxis

Indicated for the treatment of hypertension alone or with other antihypertensive agents, and for the treatment of enlarged prostate

Indicated for the treatment of mild to moderate dementia of the Alzheimer's type

Indicated for the treatment of moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers

Indicated for the treatment of Alzheimer's disease. Treatment with Kisunla should be initiated in patient with mild cognitive impairment or mild dementia stage of disease, the population in which the treatment was initiated in the clinical trials

Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management

Indicated for the treatment of erectile dysfunction

A biosimilar to Stelara; indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and moderately to severely active ulcerative colitis

A new chewable tablet indicated for the treatment of erectile dysfunction, and the signs and symptoms of benign prostatic hyperplasia

Indicated for the treatment of HIV-1 infection, in combination with other antiretroviral agents

Indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure

Indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression

A biosimilar of Stelara^®, this drug is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis

A long-acting, atypical antipsychotic indicated for the treatment of schizophrenia

A first-in-class biologic indicated for the treatment of pulmonary arterial hypertension to increase exercise capacity and reduce the risk of clinical worsening events

Indicated for the treatment of pulmonary arterial hypertension, both in patients who are treatment naïve or who are already on an ERA, PDE5 inhibitor or both

Indicated for the treatment of hypertension in combination with other antihypertensive drugs to lower blood pressure

A biosimilar to Humira, this drug is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, ankylosing spondylitis, and plaque psoriasis

Indicated for the treatment of HIV-1 infection

Indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate

Indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily

Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in obese adults, or overweight adults with at least one weight-related comorbidity

Indicated as an adjunct to diet and exercise to improve glycemic control of type 2 diabetes

Indicated for erosive esophagitis and the relief of heartburn associated with erosive esophagitis

Indicated for the maintenance treatment of moderate to severe ulcerative colitis or moderate to severe Crohn’s disease, following treatment with an infliximab product administered intravenously

A first-in-class agent indicated for the treatment of moderate to severe ulcerative colitis

A biosimilar to Stelara, indicated for the treatment of moderate to severe plaque psoriasis in patients who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, moderate to severe Crohn’s disease, and moderate to severe ulcerative colitis

Indicated for the treatment of moderate to severe ulcerative colitis

Indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis, and other autoimmune conditions, this drug is now available in an intravenous formulation

Indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Indicated for the short term management of mild to moderate acute pain, and the management of moderate to severe pain as an adjunct to opioid analgesics, this drug is now available in an intravenous formulation

Indicated for the treatment of rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs)

Indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis

Indicated for the treatment of major depressive disorder (MDD), a first-in-class drug that selectively targets the serotonin 1A receptor

Indicated for the topical treatment of plaque psoriasis

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate

Indicated for the emergency treatment of known or suspected opioid overdose, this drug is the second over-the-counter nonprescription opioid overdose drug approved by the FDA

For the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema

For the treatment of hypertension and coronary artery disease

Indicated for the treatment of spasticity resulting from multiple sclerosis, as well as in patients with spinal cord injuries or diseases.

Indicated for the management of selected, refractory, patients with epilepsy, on stable regimens of anti-epileptic drugs, who require intermittent use of diazepam to control bouts of increased seizure activity

Indicated for the control of absence (petit mal) seizures that are refractory to other drugs

A biosimilar to Humira (adalimumab) this drug is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s Disease, ulcerative colitis, and plaque psoriasis

Indicated for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19

Indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes

Indicated for the emergency treatment of known or suspected opioid overdose. This is the first approval of nalmefene hydrochloride nasal spray for health care and community use

Indicated for the treatment of moderate to severe opioid use disorder (OUD). Brixadi is administered in a healthcare setting and is available in weekly or monthly formulations, each at various dosages

Indicated for the treatment of partial-onset seizures in adults

Indicated for the treatment of schizophrenia or as maintenance monotherapy treatment of bipolar I disorder

Indicated for the treatment of schizophrenia in adults

Indicated for the acute treatment of migraine with or without aura

Indicated for the short term management of mild to moderate acute pain

Indicated for the treatment of partial-onset or primary generalized tonic-clonic seizures, adjunctive therapy for partial-onset, primary generalized tonic-clonic seizures, seizures associated with Lennox-Gastaut syndrome (LGS), and preventive treatment of migraine

Temporarily relieves minor aches and pains due to headache, toothache, backache, menstrual cramps, muscular aches, minor pain of arthritis

Indicated for the treatment of Alzheimer’s in patients with mild cognitive impairment or mild dementia sage of the disease